Printer-FriendlySAN ANTONIO, TX (Apr 17, 2012) – Mission Pharmacal announced today that it has entered into a patent and technology licensing agreement with EffRx Pharmaceuticals SA, Freienbach, Switzerland, for the manufacturing and commercialization of BINOSTO™ (alendronate sodium) Effervescent Tablets in the United States and Canada. The U.S. Food and Drug Administration recently approved BINOSTO to treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. BINOSTO will be available in the United States in late 2012.
Press Releases
Get up-to-date news from Mission Pharmacal Company and find out about our new products, recent announcements from Mission, and our latest innovations.
Click on any of the links to read the release. For older releases, use the links at the bottom of the page to see the press releases from that year.
Apr 3, 2012
SAN ANTONIO, TX (Apr 3, 2012) – Every newborn baby should enter this world healthy. The people at Mission Pharmacal Company and March of Dimes are dedicated to doing their best to make sure this happens. That's why Mission Pharmacal is proud to serve as a national corporate sponsor of March of Dimes March for Babies, for the third consecutive year.
Mar 5, 2012
SAN ANTONIO, TX (March 5, 2012) - Over the past several days, Mission Pharmacal Company has been mistakenly targeted as part of a consumer boycott of companies that currently advertise on The Rush Limbaugh Show. Mission Pharmacal has not advertised on the program in question for several years. Further, the company does not have any current endorsement agreements with Mr. Limbaugh or anyone affiliated with his program.
Feb 6, 2012
San Antonio, TX (February 2, 2012) – Mission Pharmacal Company recently acquired the prescription barrier cream Eletone® Cream, from Ferndale Healthcare, Inc. of Ferndale, Michigan. Eletone Cream is a non-steroidal, barrier cream approved by the Food and Drug Administration for the long term treatment of atopic dermatitis, an inflammatory, chronically relapsing, non-contagious and pruritic or itchy skin disorder.
Jan 26, 2012
San Antonio, TX (January 26, 2012) – Mission Pharmacal Company announces the recent formation of Alamo Pharma Services. This new business unit, a wholly owned subsidiary of Mission, will provide pharmaceutical sales teams with operational and human resources (HR) support. Alamo will be headquartered in Doylestown, Pennsylvania, expanding Mission’s Northeastern United States presence which also includes the company’s Commercial Group operations and BioComp Pharma, Mission’s lifecycle management and generics company.
